A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Trial Profile

A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Pardoprunox (Primary) ; Pramipexole
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms VERMEER
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2012 Company added in the association field as reported by EudraCT.
    • 29 Jun 2012 Planned number of patients changed from 330 to 390 as reported by EudraCT.
    • 17 Jun 2010 Results presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top